MAZE THERAPEUTICS, INC. (MAZE) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$48.03M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$26.55M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$32.97M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$36.47M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$48.03M | (m) | $0.00* | (m) | $107.00K* | -$15.05M* | (m) | $34.94M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$26.55M | (m) | $20.00M | (m) | $93.00K | -$39.11M | (m) | $34.15M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$32.97M | (m) | (m) | (m) | $68.00K* | -$24.64M* | (m) | $25.19M | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$36.47M | (m) | $0.00 | (m) | $393.00K* | -$30.05M* | (m) | $28.11M | (m) | $0.00 |
| 2025-03-31 | Reported | (m) | -$35.40M | (m) | (m) | (m) | $299.00K | -$29.52M | (m) | $27.58M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$24.23M | (m) | $2.50M | (m) | $103.00K* | -$23.20M* | (m) | $19.86M | (m) | -$279.00K |
| 2024-06-30 | Reported | (m) | $139.56M | (m) | $165.00M | (m) | $160.00K* | $145.05M* | (m) | $19.55M | (m) | $1.73M |
| 2024-03-31 | Reported | (m) | -$28.01M | (m) | (m) | (m) | $279.00K | -$23.44M | (m) | $21.88M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$142.90M | (m) | (m) | (m) | $794.00K | -$111.94M | (m) | $108.45M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | $57.59M | (m) | $167.50M | (m) | $1.15M | $75.95M | (m) | $83.50M | (m) | $1.17M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |